These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 11799926)
1. Antiangiogenic activity of selenium in cancer chemoprevention: metabolite-specific effects. Lu J; Jiang C Nutr Cancer; 2001; 40(1):64-73. PubMed ID: 11799926 [TBL] [Abstract][Full Text] [Related]
2. Selenium-induced inhibition of angiogenesis in mammary cancer at chemopreventive levels of intake. Jiang C; Jiang W; Ip C; Ganther H; Lu J Mol Carcinog; 1999 Dec; 26(4):213-25. PubMed ID: 10569799 [TBL] [Abstract][Full Text] [Related]
3. Monomethyl selenium--specific inhibition of MMP-2 and VEGF expression: implications for angiogenic switch regulation. Jiang C; Ganther H; Lu J Mol Carcinog; 2000 Dec; 29(4):236-50. PubMed ID: 11170262 [TBL] [Abstract][Full Text] [Related]
4. Selenium and cancer chemoprevention: hypotheses integrating the actions of selenoproteins and selenium metabolites in epithelial and non-epithelial target cells. Lü J; Jiang C Antioxid Redox Signal; 2005; 7(11-12):1715-27. PubMed ID: 16356132 [TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic treatment with linomide as chemoprevention for prostate, seminal vesicle, and breast carcinogenesis in rodents. Joseph IB; Vukanovic J; Isaacs JT Cancer Res; 1996 Aug; 56(15):3404-8. PubMed ID: 8758902 [TBL] [Abstract][Full Text] [Related]
6. Activities of structurally-related lipophilic selenium compounds as cancer chemopreventive agents. Ip C; Lisk DJ; Ganther HE Anticancer Res; 1998; 18(6A):4019-25. PubMed ID: 9891440 [TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo studies of methylseleninic acid: evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. Ip C; Thompson HJ; Zhu Z; Ganther HE Cancer Res; 2000 Jun; 60(11):2882-6. PubMed ID: 10850432 [TBL] [Abstract][Full Text] [Related]
8. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925 [TBL] [Abstract][Full Text] [Related]
9. Chemical form of selenium, critical metabolites, and cancer prevention. Ip C; Hayes C; Budnick RM; Ganther HE Cancer Res; 1991 Jan; 51(2):595-600. PubMed ID: 1824684 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of angiogenesis by the cancer chemopreventive agent conjugated linoleic acid. Masso-Welch PA; Zangani D; Ip C; Vaughan MM; Shoemaker S; Ramirez RA; Ip MM Cancer Res; 2002 Aug; 62(15):4383-9. PubMed ID: 12154044 [TBL] [Abstract][Full Text] [Related]
12. Cancer chemoprevention: selenium as a prooxidant, not an antioxidant. Drake EN Med Hypotheses; 2006; 67(2):318-22. PubMed ID: 16574336 [TBL] [Abstract][Full Text] [Related]
13. Interactive effects of selenium and chromium on mammary tumor development and growth in MMTV-infected female mice and their relevance to human cancer. Schrauzer GN Biol Trace Elem Res; 2006 Mar; 109(3):281-92. PubMed ID: 16632896 [TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1. Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272 [TBL] [Abstract][Full Text] [Related]
15. Anti-angiogenic potential of a cancer chemopreventive flavonoid antioxidant, silymarin: inhibition of key attributes of vascular endothelial cells and angiogenic cytokine secretion by cancer epithelial cells. Jiang C; Agarwal R; Lü J Biochem Biophys Res Commun; 2000 Sep; 276(1):371-8. PubMed ID: 11006131 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms. Huh JI; Calvo A; Stafford J; Cheung M; Kumar R; Philp D; Kleinman HK; Green JE Oncogene; 2005 Jan; 24(5):790-800. PubMed ID: 15592523 [TBL] [Abstract][Full Text] [Related]
17. Down-regulation of vascular endothelial growth factor by tissue inhibitor of metalloproteinase-2: effect on in vivo mammary tumor growth and angiogenesis. Hajitou A; Sounni NE; Devy L; Grignet-Debrus C; Lewalle JM; Li H; Deroanne CF; Lu H; Colige A; Nusgens BV; Frankenne F; Maron A; Yeh P; Perricaudet M; Chang Y; Soria C; Calberg-Bacq CM; Foidart JM; Noël A Cancer Res; 2001 Apr; 61(8):3450-7. PubMed ID: 11309307 [TBL] [Abstract][Full Text] [Related]
18. Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression. Li D; Williams JI; Pietras RJ Oncogene; 2002 Apr; 21(18):2805-14. PubMed ID: 11973639 [TBL] [Abstract][Full Text] [Related]
19. Retinoic acid and interferon alpha act synergistically as antiangiogenic and antitumor agents against human head and neck squamous cell carcinoma. Lingen MW; Polverini PJ; Bouck NP Cancer Res; 1998 Dec; 58(23):5551-8. PubMed ID: 9850093 [TBL] [Abstract][Full Text] [Related]
20. Up-Regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth. Nör JE; Christensen J; Liu J; Peters M; Mooney DJ; Strieter RM; Polverini PJ Cancer Res; 2001 Mar; 61(5):2183-8. PubMed ID: 11280784 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]